Abstract
Actinic keratosis (AK) is a common skin disease which can potentially progress to invasive squamous cell carcinoma (iSCC). Given that mortality rates and health-care cost associated with iSCC are substantial, the management of AK represents an important public health issue. Several effective lesion-directed and field-directed treatments are available. Ablative procedures (e.g. cryosurgery, excision, laser ablation, curettage alone or with electrodessication) are considered cost-effective options for solitary lesions. Field-directed therapies (e.g. Ingenol Mebutate, imiquimod, PDT, 5-Fluorouracile, diclofenac 3%, 5-FU + Salicylic acid) can be used over large epidermal surfaces and are directed to treat both individual visible lesions and cancerization fields. In order to provide guidance for management choice in clinical practice, several guidelines concerning the diagnosis and treatment of AK have been published in the past decade. However, the introduction of novel therapeutic options requires continuous updates of recommendations and adaptation to national contexts. The present review summarizes the existing evidence and reports the results of a consensus workshop on the management of AK.
| Original language | English |
|---|---|
| Pages (from-to) | 1077-1084 |
| Number of pages | 8 |
| Journal | Journal of the European Academy of Dermatology and Venereology |
| Volume | 30 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 1 2016 |
Fingerprint
ASJC Scopus subject areas
- Dermatology
- Infectious Diseases
Cite this
Italian expert consensus for the management of actinic keratosis in immunocompetent patients. / Peris, K.; Calzavara-Pinton, P. G.; Neri, L.; Girolomoni, G.; Malara, G.; Parodi, A.; Piaserico, S.; Rossi, R.; Pellacani, G.
In: Journal of the European Academy of Dermatology and Venereology, Vol. 30, No. 7, 01.07.2016, p. 1077-1084.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Italian expert consensus for the management of actinic keratosis in immunocompetent patients
AU - Peris, K.
AU - Calzavara-Pinton, P. G.
AU - Neri, L.
AU - Girolomoni, G.
AU - Malara, G.
AU - Parodi, A.
AU - Piaserico, S.
AU - Rossi, R.
AU - Pellacani, G.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Actinic keratosis (AK) is a common skin disease which can potentially progress to invasive squamous cell carcinoma (iSCC). Given that mortality rates and health-care cost associated with iSCC are substantial, the management of AK represents an important public health issue. Several effective lesion-directed and field-directed treatments are available. Ablative procedures (e.g. cryosurgery, excision, laser ablation, curettage alone or with electrodessication) are considered cost-effective options for solitary lesions. Field-directed therapies (e.g. Ingenol Mebutate, imiquimod, PDT, 5-Fluorouracile, diclofenac 3%, 5-FU + Salicylic acid) can be used over large epidermal surfaces and are directed to treat both individual visible lesions and cancerization fields. In order to provide guidance for management choice in clinical practice, several guidelines concerning the diagnosis and treatment of AK have been published in the past decade. However, the introduction of novel therapeutic options requires continuous updates of recommendations and adaptation to national contexts. The present review summarizes the existing evidence and reports the results of a consensus workshop on the management of AK.
AB - Actinic keratosis (AK) is a common skin disease which can potentially progress to invasive squamous cell carcinoma (iSCC). Given that mortality rates and health-care cost associated with iSCC are substantial, the management of AK represents an important public health issue. Several effective lesion-directed and field-directed treatments are available. Ablative procedures (e.g. cryosurgery, excision, laser ablation, curettage alone or with electrodessication) are considered cost-effective options for solitary lesions. Field-directed therapies (e.g. Ingenol Mebutate, imiquimod, PDT, 5-Fluorouracile, diclofenac 3%, 5-FU + Salicylic acid) can be used over large epidermal surfaces and are directed to treat both individual visible lesions and cancerization fields. In order to provide guidance for management choice in clinical practice, several guidelines concerning the diagnosis and treatment of AK have been published in the past decade. However, the introduction of novel therapeutic options requires continuous updates of recommendations and adaptation to national contexts. The present review summarizes the existing evidence and reports the results of a consensus workshop on the management of AK.
UR - http://www.scopus.com/inward/record.url?scp=84976487385&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976487385&partnerID=8YFLogxK
U2 - 10.1111/jdv.13648
DO - 10.1111/jdv.13648
M3 - Review article
C2 - 27060910
AN - SCOPUS:84976487385
VL - 30
SP - 1077
EP - 1084
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
SN - 0926-9959
IS - 7
ER -